 Accordingly, the main objective of this study is to pilot a 26-week trial of EXER among asymptomatic, middle-aged adults with and without family history FH of AD enrolled in the Wisconsin Registry for Alzheimers Prevention WRAP or the Wisconsin Alzheimers Disease Research Center WADRC. The investigators near-term goal is to assess the feasibility and acceptability of this structured intervention and preliminarily evaluate i its effect on AD-relevant outcomes such as glucose metabolism and ii the mechanism for such effects. The investigators longer-term goal is to use the data gathered via this pilot to further refine the intervention, estimate effect sizes for key outcomes, and seek NIH funding for a longer and more definitive assessment of whether EXER can effectively curtail AD progression in midlife. The specific aims are: 